A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " Biocytogen Boston Corp

Biocytogen Boston Corp

Table of Contents

This article introduces Biocytogen Boston Corp, a biotechnology company headquartered in Beijing, China.

To expand its efforts in antibody drug development, the company has established two divisions. One is BioMice, a contract research division that provides non-clinical study support to pharmaceutical companies, biotech firms, and academic institutions. The other focuses on the discovery and development of new antibody drugs for licensing and partnership opportunities.

Features of Biocytogen Boston Corp’s Contract Non-Clinical Research Services

Comprehensive support from early-stage drug discovery to IND submission

Before a drug can enter the market, it must undergo thorough evaluation of its efficacy, safety, and mechanism of action. Biocytogen Boston Corp provides custom gene editing services, animal and cell models, and comprehensive in vivo, ex vivo, and in vitro pharmacological testing to support efficient drug discovery from the earliest stages through IND submission.

In addition, the company offers a wide selection of established animal and cell models to accelerate research timelines.

Focus on a wide range of therapeutic areas

Biocytogen Boston Corp provides solutions with diverse disease models and integrated services to advance drug development across multiple therapeutic areas. This includes immuno-oncology, oncology, autoimmune diseases, inflammatory diseases, and neurological disorders.

Operation of large-scale animal facilities

In addition to its 55,000-square-meter SPF facility in Haimen, Jiangsu Province inChina, Biocytogen Boston Corp also operates smaller facilities in Daxing, Beijing in China, and Boston, USA. The Haimen Animal Center has been AAALAC-accredited since 2016, and the Beijing Animal Center has been certified since 2021. The company’s satellite facility in Boston also complies with the same international standards.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Example of Biocytogen Boston Corp’s Disease Models

Biocytogen provides a variety of disease models across different therapeutic areas. In oncology and immuno-oncology, one of the company's proprietary models include cell line-derived xenograft (CDX) models, in which human tumor cell lines are transplanted into immunodeficient mice, as well as humanized immune checkpoint mouse models.

Many other Models are also available for respiratory diseases such as asthma and pulmonary fibrosis, and for dermatological conditions such as psoriasis and atopic dermatitis.

Biocytogen Boston Corp Non-Clinical Case Studies

No specific case studies were available on the official website.

Company Information

In addition to its headquarters in Beijing, Biocytogen Boston Corp has offices in Nantong, Jiangsu Province, and in Boston, USA.

Address	No. 12 Baoshan South Street, Daxing Biomedical Industry Base, Daxing District, Beijing, China
Tel	+86 (010) 56967680
Website	https://biocytogen.com/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us